Webinar Scheduled for 5:30 AM PT / 8:30 AM ET SOUTH SAN FRANCISCO, Calif. , May 26, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that

ALLO-501 in Combination with ALLO-647 Based Lymphodepletion Regimen was Well Tolerated With No Dose-Limiting Toxicities or Evidence of Graft-vs-Host Disease Abstract Based on Data Cutoff in January 2020 Represents Limited Data Set of Nine Evaluable Patients Treated at Lower Dose (39mg) ALLO-647;

Oral Presentation of Initial Results from the Phase 1 ALLO-501 ALPHA Trial in Relapsed/Refractory Non-Hodgkin Lymphoma at the Virtual American Society of Clinical Oncology (ASCO) Annual Meeting Phase 1 ALPHA2 Trial for ALLO-501A, the Next Generation anti-CD19 AlloCAR T™ Intended for Phase 2

Oral Presentation is the First Data Readout from this Dose Escalation Study of ALLO-501, an Allogeneic Anti-CD19 CAR T Therapy ALPHA Study Utilizes ALLO-647 Administered as Part of its Differentiated Lymphodepletion Platform Phase 1 Study Continues Enrollment to Optimize Lymphodepletion SOUTH SAN

Company Developed TurboCAR™ Technology Allows Cytokine Activation Signaling to be Engineered Selectively into CAR T Cells Preclinical Studies Provide Evidence That Cytokine Signaling Can Increase TurboCAR T Cell Activity While Avoiding Safety Risks of Exogenous Cytokine Administration SOUTH SAN

Conference Call and Webcast Scheduled for 5:30 AM PT / 8:30 AM ET SOUTH SAN FRANCISCO, Calif. , April 27, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer,

SOUTH SAN FRANCISCO, Calif. , April 01, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in two upcoming

Initial Results from the Phase 1 ALLO-501 ALPHA Trial in Relapsed/Refractory Non-Hodgkin Lymphoma and Phase 1 ALLO-715 UNIVERSAL Trial in Relapsed/Refractory Multiple Myeloma On-Track for Q2 2020 and Q4 2020, Respectively ALLO-501A, the Next Generation anti-CD19 AlloCAR T Intended for Phase 2

Conference Call and Webcast Scheduled for 5:30 AM PT / 8:30 AM ET SOUTH SAN FRANCISCO, Calif. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer,

SOUTH SAN FRANCISCO, Calif. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at two investor